<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="covid_vaccine/PMC7472682/results/search/disease/results.xml">
  <result pre="pandemic. Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) is the most formidable challenge to"/>
  <result pre="brought the world to a standstill. The respiratory viral pathogen" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) has infected at least 20.1 million"/>
  <result pre="in the early phase of infection resulting from innate immune" exact="suppression" post="probably underpins the ensuing dysregulated inflammatory responses16,21, particularly in"/>
  <result pre="burden and dysregulated, potentially lethal, inflammatory responses and immunopathology, including" exact="acute respiratory distress syndrome." post="For this reason, seniors and those with co-morbidities may"/>
  <result pre="are under way to assess the effects of BCG or" exact="measles" post="vaccination on COVID-19 (ref.178). A COVID-19 vaccine that can"/>
  <result pre="might enhance early viral control by overcoming virus-imposed innate immune" exact="suppression" post="and facilitating adaptive immune activation. The early timing of"/>
  <result pre="As respiratory mucosal immunity is key to early clearance of" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2), inducing trained immunity in alveolar macrophages"/>
  <result pre="virus, they have been reported to provide protection against mouse" exact="hepatitis" post="virus, a coronavirus of mice. Notably, these antibodies were"/>
  <result pre="immunity Whereas the current successful human antiviral vaccines, such as" exact="influenza" post="and measles vaccines, depend largely on the induction of"/>
  <result pre="the current successful human antiviral vaccines, such as influenza and" exact="measles" post="vaccines, depend largely on the induction of antibody responses,"/>
  <result pre="SARS-CoV-2 infection is associated not only with virus-mediated innate immune" exact="suppression" post="but also with delayed activation of T cells, particularly"/>
  <result pre="whereas TH2 cell responses have been associated with enhancement of" exact="lung disease" post="following infection in hosts parenterally vaccinated with inactivated SARS-CoV"/>
  <result pre="specific for SARS-CoV-2 and CD4+ T cells specific for human" exact="common cold" post="coronaviruses, SARS-CoV and animal betacoronaviruses17,59–61. There are four human"/>
  <result pre="adults also have IgG antibodies specific for all four human" exact="common cold" post="coronaviruses17. However, similarly to antibody responses to SARS-CoV and"/>
  <result pre="vaccinated with experimental SARS-CoV vaccines. Ferrets vaccinated with a modified" exact="vaccinia virus" post="Ankara (MVA) vaccine expressing full-length S protein had increased"/>
  <result pre="(MVA) vaccine expressing full-length S protein had increased infection and" exact="hepatitis" post="following challenge71,72. Antibodies to S protein were reported to"/>
  <result pre="2 Safety considerations for COVID-19 vaccinesAs most individuals infected with" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) are asymptomatic or develop only mild"/>
  <result pre="known whether it protects against RM viral pathogens Measles and" exact="influenza" post="viruses (replicating) S protein? Quality and durability depend on"/>
  <result pre="Not extensively tested in humans; potential recombination of live attenuated" exact="influenza" post="vectors in the lung delivered via RM route Other"/>
  <result pre="papillomavirus; IM, intramuscular; RBD, receptor-binding domain; RM, respiratory mucosal; SARS-CoV-2," exact="severe acute respiratory syndrome" post="coronavirus 2; S protein, spike protein; SC, subcutaneous; TH"/>
  <result pre="helper cell; TRM cell, resident memory T cell; VSV, vesicular" exact="stomatitis" post="virus. Vaccination routes and regimens In addition to the"/>
  <result pre="this being the primary mechanism by which intramuscular injection of" exact="measles" post="or influenza vaccine offers protection in humans. However, this"/>
  <result pre="the primary mechanism by which intramuscular injection of measles or" exact="influenza" post="vaccine offers protection in humans. However, this route of"/>
  <result pre="repeated doses of IM injection Published data showing prevention of" exact="pneumonia" post="but not transmission in NHPs Published data showing safety"/>
  <result pre="NHP, non-human primate; RBD, receptor-binding domain; saRNA, self-amplifying RNA; SARS-CoV-2," exact="severe acute respiratory syndrome" post="coronavirus 2; S protein, spike protein; TH1 cell, T"/>
  <result pre="spike protein; TH1 cell, T helper 1 cell; VSV, vesicular" exact="stomatitis" post="virus. aSelected for US Operation Warp Speed. Box 3"/>
  <result pre="number of animal species have differing degrees of susceptibility to" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2) infection, depending on the relative binding"/>
  <result pre="SARS-CoV-2 replication in the lung, and these mice develop interstitial" exact="pneumonia" post="similar to humans188. Human ACE2-expressing mice that are further"/>
  <result pre="attenuated viral vaccines Historically, several successful human vaccines, such as" exact="measles" post="vaccine and the bacillus Calmette–Guérin (BCG) vaccine for tuberculosis"/>
  <result pre="as measles vaccine and the bacillus Calmette–Guérin (BCG) vaccine for" exact="tuberculosis" post="(TB), have been based on attenuated strains of the"/>
  <result pre="on the vaccine strains of other human pathogens (such as" exact="measles" post="or influenza viruses) or veterinary pathogens (such as vesicular"/>
  <result pre="vaccine strains of other human pathogens (such as measles or" exact="influenza" post="viruses) or veterinary pathogens (such as vesicular stomatitis virus"/>
  <result pre="measles or influenza viruses) or veterinary pathogens (such as vesicular" exact="stomatitis" post="virus (VSV)). However, it will be important to consider"/>
  <result pre="nCoV-19 reduced SARS-CoV-2 viral load in the lungs and prevented" exact="pneumonia" post="in rhesus macaques, it did not reduce viral loads"/>
  <result pre="viruses have been used successfully in human vaccines against polio," exact="hepatitis" post="A and influenza121,122. Inactivated viruses can be rapidly generated"/>
  <result pre="in aged hosts56,74,129. Although PiCoVacc or BBIBP-CorV did not worsen" exact="lung disease" post="within 7 days after infection, alum is known to"/>
  <result pre="that are co-expressed or admixed. Several commercial vaccines, such as" exact="hepatitis" post="B and human papillomavirus vaccines, are based on VLPs137."/>
  <result pre="use, their potential is supported by previous studies of influenza," exact="rabies" post="and Zika virus infections in animals149–153. For example, an"/>
  <result pre="virus infections in animals149–153. For example, an mRNA vaccine for" exact="influenza" post="virus induced long-term humoral immunity in young and aged"/>
  <result pre="on the successful experience in respiratory mucosal delivery of influenza," exact="measles" post="and TB vaccines to humans160–162. Respiratory mucosal vaccination also"/>
  <result pre="coronavirus disease 2019 (COVID-19) pandemic and the host response to" exact="severe acute respiratory syndrome" post="coronavirus 2 (SARS-CoV-2). One scenario is the priority vaccination"/>
  <result pre="rapidly developing lung condition characterized by deficient oxygen exchange and" exact="shortness" post="of breath, resulting from severe lung injury and inflammation"/>
  <result pre="COVID-19 in EuropeNature202058425726132512579 4.SancheSet al.High contagiousness and rapid spread of" exact="severe acute respiratory syndrome" post="coronavirus 2Emerg. Infect. Dis.2020261470147732255761 5.World Health Organization. Draft landscape"/>
  <result pre="sides of the same coin: friends or foes?Front. Immunol.20178196029375577 26.HaqKMcElhaneyJEImmunosenescence:" exact="influenza" post="vaccination and the elderlyCurr. Opin. Immunol.201429384224769424 27.TayMZPohCMRéniaLMacAryPANgLFPThe trinity of"/>
  <result pre="COVID-19Nat. Med.20202684584832350462 41.NakanagaKYamanouchiKFujiwaraKProtective effect of monoclonal antibodies on lethal mouse" exact="hepatitis" post="virus infection in miceJ. Virol.1986591681713012115 42.LecomteJet al.Protection from mouse"/>
  <result pre="hepatitis virus infection in miceJ. Virol.1986591681713012115 42.LecomteJet al.Protection from mouse" exact="hepatitis" post="virus type 3-induced acute disease by an anti-nucleoprotein monoclonal"/>
  <result pre="for protection from clinical disease and for virus clearance in" exact="severe acute respiratory syndrome" post="coronavirus-infected miceJ. Virol.2010849318932520610717 51.TurnerDLet al.Lung niches for the generation"/>
  <result pre="generation and maintenance of tissue-resident memory T cellsMucosal Immunol.2014750151024064670 52.JeyanathanMYaoYAfkhamiSSmaillFXingZNew" exact="tuberculosis" post="vaccine strategies: taking aim at un-natural immunityTrends Immunol.20183941943329429859 53.HaddadiSet"/>
  <result pre="response in SARS coronavirus infectionEmerg. Microbes Infect.2012116 56.BollesMet al.A double-inactivated" exact="severe acute respiratory syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
  <result pre="cells cross-reactive to SARS-CoV-2, likely resulting from previous exposure to" exact="common cold" post="coronaviruses as well as animal coronaviruses. These findings offer"/>
  <result pre="of infection for SARS-CoV-2 countermeasuresNat. Biotechnol.20203878979132504046 71.WeingartlHet al.Immunization with modified" exact="vaccinia virus" post="Ankara-based recombinant vaccine against severe acute respiratory syndrome is"/>
  <result pre="71.WeingartlHet al.Immunization with modified vaccinia virus Ankara-based recombinant vaccine against" exact="severe acute respiratory syndrome" post="is associated with enhanced hepatitis in ferretsJ. Virol.200478126721267615507655 72.CzubMWeingartlHCzubSHeRCaoJEvaluation"/>
  <result pre="vaccine against severe acute respiratory syndrome is associated with enhanced" exact="hepatitis" post="in ferretsJ. Virol.200478126721267615507655 72.CzubMWeingartlHCzubSHeRCaoJEvaluation of modified vaccinia virus Ankara"/>
  <result pre="associated with enhanced hepatitis in ferretsJ. Virol.200478126721267615507655 72.CzubMWeingartlHCzubSHeRCaoJEvaluation of modified" exact="vaccinia virus" post="Ankara based recombinant SARS vaccine in ferretsVaccine2005232273227915755610 73.KamYWet al.Antibodies"/>
  <result pre="pandemicCell Host Microbe20202769970332407708 75.BuchholzUJet al.Contributions of the structural proteins of" exact="severe acute respiratory syndrome" post="coronavirus to protective immunityProc. Natl Acad. Sci.20041019804980915210961 76.StephensenCBCaseboltDBGangopadhyayNNPhylogenetic analysis"/>
  <result pre="coronavirus as a vaccine candidateMBio20134e00650-1324023385 88.NetlandJet al.Immunization with an attenuated" exact="severe acute respiratory syndrome" post="coronavirus deleted in E protein protects against lethal respiratory"/>
  <result pre="in the cytoplasmic tail of spike protein attenuates porcine epidemic" exact="diarrhea" post="virus in pigsJ. Virol.201893e01758-18 90.Jimenez-GuardeñoJMet al.Identification of the mechanisms"/>
  <result pre="a genetically stable vaccinePLoS Pathog.201511e100521526513244 91.MenacheryVDet al.Attenuation and restoration of" exact="severe acute respiratory syndrome" post="coronavirus mutant lacking 2’-O-methyltransferase activityJ. Virol.2014884251426424478444 92.ChengBYHOrtiz-RiañoENogalesAde la TorreJCMartínez-SobridoLDevelopment"/>
  <result pre="placebo-controlled, phase 2 trialLancet202010.1016/S0140-6736(20)31605-632758466 100.SmaillFet al.A human type 5 adenovirus-based" exact="tuberculosis" post="vaccine induces robust T cell responses in humans despite"/>
  <result pre="I trial evaluating the safety and immunogenicity of a candidate" exact="tuberculosis" post="vaccination regimen, ChAdOx1 85A prime – MVA85A boost in"/>
  <result pre="healthy UK adultsVaccine20203877978931735500 114.van DoremalenNet al.ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2" exact="pneumonia" post="in rhesus macaquesNature202010.1038/s41586-020-2608-y32731258 115.FolegattiPMet al.Safety and immunogenicity of the"/>
  <result pre="COVID-19 vaccine and therapy plans. Science10.1126/science.abd0121 (2020). 118.CaseJBet al.Replication-competent vesicular" exact="stomatitis" post="virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in miceCell"/>
  <result pre="against SARS-CoV-2 challengebioRxiv202010.1101/2020.06.18.160655 120.KochTet al.Safety and immunogenicity of a modified" exact="vaccinia virus" post="Ankara vector vaccine candidate for Middle East respiratory syndrome:"/>
  <result pre="vaccine: past and present experienceVaccine1996147357468817819 122.VellozziCet al.Safety of trivalent inactivated" exact="influenza" post="vaccines in adults: background for pandemic influenza vaccine safety"/>
  <result pre="of trivalent inactivated influenza vaccines in adults: background for pandemic" exact="influenza" post="vaccine safety monitoringVaccine2009272114212019356614 123.WoodJMRobertsonJSFrom lethal virus to life-saving vaccine:"/>
  <result pre="in mice after immunization with the S2 subunit of the" exact="severe acute respiratory syndrome" post="coronavirusDNA Cell Biol.20052451051516101349 134.ZhouYJiangSDuLProspects for a MERS-CoV spike vaccineExpert."/>
  <result pre="formulation for clinical translationExpert. Rev. Vaccines20181783384930173619 138.LuXet al.Immune responses against" exact="severe acute respiratory syndrome" post="coronavirus induced by virus-like particles in miceImmunology200712249650217680799 139.LokugamageKGet al.Chimeric"/>
  <result pre="by virus-like particles in miceImmunology200712249650217680799 139.LokugamageKGet al.Chimeric coronavirus-like particles carrying" exact="severe acute respiratory syndrome" post="coronavirus (SCoV) S protein protect mice against challenge with"/>
  <result pre="al.Protective efficacy of in vitro synthesized, specific mRNA vaccines against" exact="influenza" post="A virus infectionNat. Biotechnol.2012301210121623159882 150.ChahalJSet al.Dendrimer-RNA nanoparticles generate protective"/>
  <result pre="doseProc. Natl Acad. Sci. USA2016113E4133E414227382155 151.SchneeMet al.An mRNA vaccine encoding" exact="rabies" post="virus glycoprotein induces protection against lethal infection in mice"/>
  <result pre="demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9" exact="influenza" post="virusesMol. Ther.2017251316132728457665 153.PardiNet al.Zika virus protection by a single"/>
  <result pre="mouse modelSci. Rep.2017725228325910 155.AlbererMet al.Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
  <result pre="vaccine protection against SARS-CoV-2 in rhesus macaquesScience202010.1126/science.abc628432820126 159.LichtyBDBreitbachCJStojdlDFBellJCGoing viral with" exact="cancer" post="immunotherapyNat. Rev. Cancer20141455956724990523 160.MohnKG-ISmithISjursenHCoxRJImmune responses after live attenuated influenza"/>
  <result pre="with cancer immunotherapyNat. Rev. Cancer20141455956724990523 160.MohnKG-ISmithISjursenHCoxRJImmune responses after live attenuated" exact="influenza" post="vaccinationHum. Vaccin. Immunother.20181457157828933664 161.LowNet al.A randomized, controlled trial of"/>
  <result pre="Engl. J. Med.20153721519152925875257 162.SattiIet al.Safety and immunogenicity of a candidate" exact="tuberculosis" post="vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults:"/>
  <result pre="with trained immunityCell Host Microbe20182389100.e529324233 175.VerrallAJet al.Early clearance of mycobacterium" exact="tuberculosis" post="is associated with increased innate immune responsesJ. Infect. Dis.201922113421350"/>
  <result pre="memory in barrier tissuesNat. Rev. Immunol.20202030832032015472 180.CardaniABoultonAKimTSBracialeTJAlveolar macrophages prevent lethal" exact="influenza" post="pneumonia by inhibiting infection of type-1 alveolar epithelial cellsPLoS"/>
  <result pre="in barrier tissuesNat. Rev. Immunol.20202030832032015472 180.CardaniABoultonAKimTSBracialeTJAlveolar macrophages prevent lethal influenza" exact="pneumonia" post="by inhibiting infection of type-1 alveolar epithelial cellsPLoS Pathog.201713e100614028085958"/>
 </snippets>
</snippetsTree>
